In the report "Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel," errors occurred in [Table 1](#T1){ref-type="table"}. The corrected [Table 1](#T1){ref-type="table"} is below.

###### Recommendations for postexposure prophylaxis and preexposure protection, by age group and risk category

  Indication/Age group             Risk category/Health status                                                       Hepatitis A vaccine   Immune globulin\*
  -------------------------------- --------------------------------------------------------------------------------- --------------------- ------------------------
  **Postexposure prophylaxis**                                                                                                             
  \<12 mos                         Healthy                                                                           No                    0.1 mL/**kg**
  12 mos--40 yrs                   Healthy                                                                           1 dose^†^             None
  \>40 yrs                         Healthy                                                                           1 dose^†^             0.1 mL/kg^§^
  ≥12 mos                          Immunocompromised or chronic liver disease                                        1 dose^†^             0.1 mL/kg^¶^
  ≥12 mos                          Vaccine contraindicated\*\*                                                       No                    0.1 mL/kg
  **Preexposure protection^††^**                                                                                                           
  \<6 mos                          Healthy                                                                           No                    0.1--0.2 mL/kg^§§^
  6--11 mos                        Healthy                                                                           1 dose^¶¶^            None
  12 mos--40 yrs                   Healthy                                                                           1 dose\*\*\*          None
  \>40 yrs                         Healthy                                                                           1 dose\*\*\*          0.1--0.2 mL/kg^§§,†††^
  **\>6 mos**                      Immunocompromised or chronic liver disease                                        1 dose\*\*\*          0.1--0.2 mL/kg^§§,†††^
  \>6 mos                          Persons who elect not to receive vaccine or for whom vaccine is contraindicated   No                    0.1--0.2 mL/kg^§§^

\* Measles, mumps, and rubella vaccine should not be administered for at least 3 months after receipt of immune globulin.

^†^ A second dose is not required for postexposure prophylaxis; however, for long-term immunity, the hepatitis A vaccination series should be completed with a second dose at least 6 months after the first dose.

^§^ The provider's risk assessment should determine the need for immune globulin administration. If the provider's risk assessment determines that both vaccine and immune globulin are warranted, Hepatitis A vaccine and immune globulin should be administered simultaneously at different anatomic sites.

^¶^ Vaccine and immune globulin should be administered simultaneously at different anatomic sites.

\*\* Life-threatening allergic reaction to a previous dose of hepatitis A vaccine, or allergy to any vaccine component.

^††^ Immune globulin should be considered before travel for persons with special risk factors for either hepatitis A virus (HAV) infection or increased risk for complications in the event of exposure to HAV.

^§§^ 0.1 mL/kg for travel up to 1 month; 0.2 mL/kg for travel up to 2 months, 0.2 mL/kg every 2 months for travel of ≥2 months' duration.

^¶¶^ This dose should not be counted toward the routine 2-dose series, which should be initiated at age 12 months.

\*\*\* For persons not previously vaccinated with HepA vaccine, administer dose as soon as travel is considered, and complete series according to routine schedule.

^†††^ May be administered, based on providers' risk assessment.
